CYNTHIA M GOLDSMITHFLETCHER MD
Prescription History 1124070941
Obstetrics & Gynecology in Anniston, AL

NPI Status: Active since May 17, 2006

Contact Information

901 LEIGHTON AVE
SUITE 501
ANNISTON, AL
ZIP 36207
Phone: (256) 237-6755
Fax: (256) 236-1823

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CYNTHIA M GOLDSMITHFLETCHER MD, an active Obstetrics & Gynecology specialist practicing in Anniston, AL. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 234 documented patient claims. Among these therapy options, the most frequently utilized medication is Raloxifene Hcl, which accounts for 79 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 40
30-Day Fills 56.2
Days Supply 1,617
AL State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills98.6
Peer Average Days Supply2,915
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $194.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.87

State Avg Cost Per Claim

$11.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 20
30-Day Fills 38.5
Days Supply 1,155
AL State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills110.3
Peer Average Days Supply3,291
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.8% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $529.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.45

State Avg Cost Per Claim

$47.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Ibandronate Sodium

Generic Formulation: Ibandronate SodiumSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 31
30-Day Fills 52.8
Days Supply 1,564
AL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills64.8
Peer Average Days Supply1,935
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,372.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.28

State Avg Cost Per Claim

$47.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.

Therapeutic Applications

Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause, as you age, or if you take corticosteroid medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Ibandronate belongs to a class of medications called bisphosphonates.

Intrarosa

Generic Formulation: Prasterone (Dhea)Specialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 21.6
Days Supply 616
AL State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills15.9
Peer Average Days Supply448
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,680.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$315.59

State Avg Cost Per Claim

$282.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used by women after menopause to treat painful sexual intercourse. Painful intercourse can be a symptom of changes in and around your vagina, due to menopause. Prasterone belongs to a class of drugs known as steroids. It is not well understood how it works to lessen painful intercourse, but prasterone is changed in the body to certain hormones (androgens and estrogens).

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
AL State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills67.4
Peer Average Days Supply1,881
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.0% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,780.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$486.30

State Avg Cost Per Claim

$602.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Prolia

Generic Formulation: DenosumabSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 65.6
Days Supply 1,968
AL State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills153.4
Peer Average Days Supply4,599
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.7% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,805.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,618.69

State Avg Cost Per Claim

$1,515.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.

Therapeutic Applications

Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 79
30-Day Fills 163.0
Days Supply 4,824
AL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply1,680
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 216.0% higher than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,070.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$89.50

State Avg Cost Per Claim

$103.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 556
AL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills35.1
Peer Average Days Supply788
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $412.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.69

State Avg Cost Per Claim

$46.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CYNTHIA M GOLDSMITHFLETCHER MD provides transparency into local medical care patterns within Anniston, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.